# Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC

> **NCT06494943** · PHASE1,PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 27 (estimated)

## Conditions studied

- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** IBI110
- **DRUG:** Paclitaxel
- **DRUG:** Cis Platinum
- **PROCEDURE:** Surgery
- **RADIATION:** Adjuvant radiation

## Key facts

- **NCT ID:** NCT06494943
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494943, "Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06494943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*